CD274 and metastatic neoplasm: Importantly, and in contrast to findings in metastatic disease, where efficacy of immunotherapy is primarily observed in PD-L1 CPS-positive tumors, CPS was not predictive of response at cut-offs of 1, 5 or 10 (Supplementary Table 2).